Svar Celebrates 20 Years of Complement Assays

• Direct contact technical support
• Find products for your research

Svar Life Science, a long-standing leader in assay innovation, celebrates the 20th anniversary of its Wieslab® Complement System Assay kits in 2025. This milestone highlights the company’s enduring commitment to advancing pharmaceutical development through cutting-edge assay solutions and CRO services.

Immunology is increasingly central to biopharma, and Svar is uniquely positioned to support the shift toward immune-driven therapies for complex, chronic, and rare diseases, as well as oncology. With roots in complement system assessment, Svar has evolved from a trusted provider of immune and cell-based assays into a strategic partner in emerging therapeutic modalities.

Since its founding in 1992, Svar has introduced pioneering technologies such as the Anti-CCP2 assay for rheumatoid arthritis and the _iLite_® cell-based reporter gene platform. Its Wieslab® kits have become global standards, supporting both clinical diagnostics and therapeutic breakthroughs.

Svar’s headquarters in Malmö house diagnostics, bioanalytical, and R&D labs, along with a production site. A specialized cell engineering center in Paris complements its capabilities. The company’s transformation from Euro Diagnostica to today’s broad portfolio reflects its dedication to meeting the evolving needs of pharma, biotech, and diagnostics.

Svar now plays a vital role in supporting advanced therapies, including AAV-based approaches, multispecific antibodies, and targeted immune therapeutics, while maintaining a strong focus on complement research. CEO Anne Thjømøe emphasizes, “We’ve built on the solid foundation of immunoassays development, but our solutions now go far beyond. We’re meeting the needs of a new era in pharmaceutical development, one defined by innovation, regulation, and precision.”

Svar’s Wieslab® kits, developed with leading experts, are recognized as the gold standard for complement system analysis. These tools are essential for clinical assessment and the development of next-generation complement-targeting drugs. The company also sponsors the annual Svar Complement Excellence Award, honoring researchers and physicians who contribute significantly to the field.

With GxP-compliant CRO services, ISO 15189-accredited clinical labs, and custom cell-based assay development, Svar ensures readiness for evolving scientific and regulatory demands. Thjømøe adds, “Today, we offer pharma and biotech uniquely adapted assay solutions that help bring sophisticated therapies to market faster, smarter, and with confidence.”

Looking ahead, Svar’s vision is clear: to accelerate immune innovation, build meaningful partnerships, and help shape a healthier future for patients worldwide.